Pacira BioSciences, Inc. (NASDAQ:PCRX) — Market Cap & Net Worth

$894.77 Million USD · Rank #9574

Market Cap & Net Worth: Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences, Inc. (NASDAQ:PCRX) has a market capitalization of $894.77 Million ($894.77 Million) as of June 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9574 globally and #2594 in its home market, demonstrating a -0.04% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacira BioSciences, Inc.'s stock price $22.74 by its total outstanding shares 39347924 (39.35 Million). Review total liabilities of Pacira BioSciences, Inc. to assess the company's total debt and financial obligations.

Pacira BioSciences, Inc. Market Cap History: 2015 to 2026

Pacira BioSciences, Inc.'s market capitalization history from 2015 to 2026. Data shows change from $3.02 Billion to $894.77 Million (-5.41% CAGR).

Index Memberships

Pacira BioSciences, Inc. is a constituent of 4 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
NASDAQ Health Care IXHC	$2.44 Trillion	0.04%	#261 of 976
NASDAQ Composite IXIC	$41.39 Trillion	0.00%	#993 of 3165
NASDAQ Biotechnology NBI	$1.70 Trillion	0.05%	#150 of 263
S&P Small-Cap 600 Index SML	$1.65 Trillion	0.10%	#488 of 602

Weight: Pacira BioSciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Pacira BioSciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Pacira BioSciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

1.40x

Pacira BioSciences, Inc.'s market cap is 1.40 times its annual revenue

Industry average: 0.52x Higher than industry average

Latest Price to Earnings (P/E) Ratio

144.77x

Pacira BioSciences, Inc.'s market cap is 144.77 times its annual earnings

Industry average: 0.02x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$1.27 Billion	$276.37 Million	-$37.95 Million	4.60x	N/A
2017	$1.80 Billion	$286.63 Million	-$42.61 Million	6.27x	N/A
2018	$1.69 Billion	$337.28 Million	-$471.00K	5.02x	N/A
2019	$1.78 Billion	$421.03 Million	-$11.02 Million	4.23x	N/A
2020	$2.35 Billion	$429.65 Million	$145.52 Million	5.48x	16.18x
2021	$2.37 Billion	$541.53 Million	$41.98 Million	4.37x	56.40x
2022	$1.52 Billion	$666.82 Million	$15.91 Million	2.28x	95.49x
2023	$1.33 Billion	$674.98 Million	$41.95 Million	1.97x	31.64x
2024	$741.31 Million	$700.97 Million	-$99.56 Million	1.06x	N/A
2025	$1.02 Billion	$726.41 Million	$7.03 Million	1.40x	144.77x

Competitor Companies of PCRX by Market Capitalization

Companies near Pacira BioSciences, Inc. in the global market cap rankings as of June 16, 2026.

Key companies related to Pacira BioSciences, Inc. by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#512	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#560	GALDERMA GROUP AG	NYSE:GALDY	$48.78 Billion	$43.41
#613	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$44.69 Billion	CN¥47.88
#629	Takeda Pharmaceutical Company Limited	F:TKDA	$43.60 Billion	€13.60

Pacira BioSciences, Inc. Historical Marketcap From 2015 to 2026

Between 2015 and today, Pacira BioSciences, Inc.'s market cap moved from $3.02 Billion to $ 894.77 Million, with a yearly change of -5.41%.

Year	Market Cap	Change (%)
2026	$894.77 Million	-12.13%
2025	$1.02 Billion	+37.37%
2024	$741.31 Million	-44.16%
2023	$1.33 Billion	-12.61%
2022	$1.52 Billion	-35.83%
2021	$2.37 Billion	+0.55%
2020	$2.35 Billion	+32.10%
2019	$1.78 Billion	+5.30%
2018	$1.69 Billion	-5.76%
2017	$1.80 Billion	+41.33%
2016	$1.27 Billion	-57.94%
2015	$3.02 Billion	--

End of Day Market Cap According to Different Sources

On Jun 16th, 2026 the market cap of Pacira BioSciences, Inc. was reported to be:

Source	Market Cap
Yahoo Finance	$894.77 Million USD
MoneyControl	$894.77 Million USD
MarketWatch	$894.77 Million USD
marketcap.company	$894.77 Million USD
Reuters	$894.77 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Pacira BioSciences, Inc.

NASDAQ:PCRX USA Drug Manufacturers - Specialty & Generic

Market Cap

$894.77 Million

Market Cap Rank

#9574 Global

#2594 in USA

Share Price

$22.74

Change (1 day)

-1.09%

52-Week Range

$19.16 - $27.22

All Time High

$81.64